SCHEMBL2563376

SCHEMBL2563376

Cc1cccc(F)c1C(=O)N1CCC[C@H](C(=O)O)[C@@H]1c1ccc(NC2CCC2)cc1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CCR5 P51681 5/20 0.40
KMT2A Q03164 3/20 0.38
PREP P48147 1/20 0.37
HCRTR1 O43613 2/20 0.37
HCRTR2 O43614 2/20 0.37
GFER P55789 2/20 0.36
MEN1 O00255 1/20 0.35
ITGB3 P05106 1/20 0.34
ITGB1 P05556 1/20 0.34
ITGAV P06756 1/20 0.34
ITGA5 P08648 1/20 0.34
ITGA4 P13612 1/20 0.34
PTGS1 P23219 1/20 0.34
PTGS2 P35354 1/20 0.34
ALDH1A1 P00352 1/20 0.34
LMNA P02545 1/20 0.34
MAPT P10636 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2586526 0.98 CCR5 (0.40) CCR5KMT2APREPHCRTR1HCRTR2
SCHEMBL18532541 0.98 CCR5 (0.40) CCR5KMT2APREPHCRTR1HCRTR2
SCHEMBL18790097 0.98 CCR5 (0.40) CCR5KMT2APREPHCRTR1HCRTR2
SCHEMBL2579732 0.97 CCR5 (0.39) CCR5KMT2APREPHCRTR1HCRTR2
SCHEMBL3343277 0.93 CCR5 (0.38) CCR5KMT2APREPHCRTR1HCRTR2
SCHEMBL3628772 0.93 CCR5 (0.38) CCR5KMT2APREPHCRTR1HCRTR2
SCHEMBL20971890 0.92 CCR5 (0.35) CCR5KMT2APREPHCRTR1HCRTR2
SCHEMBL20971889 0.92 PREP (0.36) CCR5KMT2APREPHCRTR1HCRTR2
SCHEMBL26006626 0.90 CCR5 (0.40) CCR5KMT2APREPHCRTR1HCRTR2
SCHEMBL26006228 0.90 CCR5 (0.40) CCR5KMT2APREPHCRTR1HCRTR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230102258-A1 C5AR ANTAGONISTS CHEMOCENTRYX, INC. 2023-03-30 US disclosed
EP-4015504-A1 C5AR ANTAGONISTS ChemoCentryx, Inc. (US) 2022-06-22 EP disclosed
EP-3508477-B1 C5AR ANTAGONISTS CHEMOCENTRYX INC (US) 2021-11-10 EP disclosed
US-10660897-B2 C5aR antagonists CHEMOCENTRYX, INC. (US) 2020-05-26 US disclosed
EP-3508477-A1 C5AR ANTAGONISTS ChemoCentryx, Inc. (US) 2019-07-10 EP disclosed
EP-3078658-B1 C5AR ANTAGONISTS CHEMOCENTRYX INC (US) 2019-04-10 EP disclosed
US-10035768-B2 C5aR antagonists CHEMOCENTRYX, INC. (US) 2018-07-31 US disclosed
US-20180179160-A1 C5AR ANTAGONISTS CHEMOCENTRYX, INC. 2018-06-28 US disclosed
EP-2585064-B1 C5AR ANTAGONISTS CHEMOCENTRYX INC (US) 2017-05-03 EP disclosed
US-20170114017-A1 C5AR ANTAGONISTS CHEMOCENTRYX, INC. 2017-04-27 US disclosed
US-20130317028-A1 C5aR ANTAGONISTS CHEMOCENTRYX, INC. (US) 2013-11-28 US disclosed
US-20130172347-A1 C5AR ANTAGONISTS CHEMOCENTRYX, INC. 2013-07-04 US disclosed
US-8445515-B2 C5aR antagonists CHEMOCENTRYX, INC. (US) 2013-05-21 US disclosed
EP-2585064-A1 C5AR ANTAGONISTS ChemoCentryx, Inc. (US) 2013-05-01 EP disclosed
WO-2011163640-A1 C5AR ANTAGONISTS CHEMOCENTRYX, INC. (US) 2011-12-29 WO disclosed
US-20110275639-A1 C5aR ANTAGONISTS CHEMOCENTRYX, INC. (US) 2011-11-10 US disclosed
EP-2381778-A1 C5AR ANTAGONISTS ChemoCentryx, Inc. (US) 2011-11-02 EP disclosed
US-20100311753-A1 C5aR ANTAGONISTS CHEMOCENTRYX, INC. (US) 2010-12-09 US disclosed
WO-2010075257-A1 C5AR ANTAGONISTS CHEMOCENTRYX, INC. (US) 2010-07-01 WO disclosed
US-20100160320-A1 C5aR ANTAGONISTS CHEMOCENTRYX, INC. (US) 2010-06-24 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160320-A1 C5aR ANTAGONISTS C5AR1, C5AR2, C3AR1 CCR5 78/4885KMT2A 4442/4885PREP 597/4885
US-10660897-B2 C5aR antagonists C5AR1, C5AR2, C3AR1 CCR5 78/4885KMT2A 4442/4885PREP 597/4885
US-20110275639-A1 C5aR ANTAGONISTS C5AR1, C5AR2, C3AR1 CCR5 78/4885KMT2A 4442/4885PREP 597/4885
US-20170114017-A1 C5AR ANTAGONISTS C5AR1, C5AR2, C3AR1 CCR5 78/4885KMT2A 4442/4885PREP 597/4885
US-20180179160-A1 C5AR ANTAGONISTS C5AR1, C5AR2, C3AR1 CCR5 78/4885KMT2A 4442/4885PREP 597/4885
US-10035768-B2 C5aR antagonists C5AR1, C5AR2, C3AR1 CCR5 78/4885KMT2A 4442/4885PREP 597/4885
US-20130317028-A1 C5aR ANTAGONISTS C5AR1, C5AR2, C3AR1 CCR5 78/4885KMT2A 4442/4885PREP 597/4885
US-20230102258-A1 C5AR ANTAGONISTS C5AR1, C5AR2, C3AR1 CCR5 78/4885KMT2A 4442/4885PREP 597/4885
US-20100311753-A1 C5aR ANTAGONISTS C5AR1, C5AR2, C3AR1 CCR5 78/4885KMT2A 4442/4885PREP 597/4885
US-20130172347-A1 C5AR ANTAGONISTS C5AR1, C5AR2, C3AR1 CCR5 78/4885KMT2A 4442/4885PREP 597/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.